MedPath
HSA Approval

MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG

SIN17018P

MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG

MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG

June 3, 2024

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

POWDER, FOR SOLUTION

ORAL

Medical Information

L01EE01

Manufacturer Information

NOVARTIS (SINGAPORE) PTE LTD

Sandoz S.R.L.

Active Ingredients

Trametinib dimethylsulfoxide 5.30 mg eqv trametinib

4.7 mg

Trametinib

Documents

Package Inserts

Mekinist PI.pdf

Approved: June 3, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

MEKINIST® POWDER FOR ORAL SOLUTION 4.7 MG - HSA Approval | MedPath